Valneva (VALN) has released an update.
Valneva SE, a specialty vaccine company, has announced submissions to extend the label of its chikungunya vaccine, IXCHIQ®, to cover adolescents in Europe and Canada, with plans for a similar extension in the U.S. The vaccine, which is already approved for use in adults, has shown promising results in adolescent trials and demonstrated two-year antibody persistence. With the U.S. launch in progress, Valneva also anticipates first sales in Canada and Europe by the fourth quarter of 2024, alongside efforts to increase accessibility in low- and middle-income countries.
For further insights into VALN stock, check out TipRanks’ Stock Analysis page.
